Condition: Heart Failure · Atrial Fibrillation · Sponsor: Daniel Rodríguez Muñoz
The PACE-FIB trial is a multicentre, randomised, open-label clinical trial. Patients older than 18 years, with permanent AF, LVEF\>40%, average resting heart rate ≤ 110 beats per minute (bpm), at least one hospitalisation due to HF in the previous year and basal NT-proBNP level\>900 pg/ml will be randomised to either CSP and subsequent AV node ablation (intervention group) vs. pharmacologic rate control optimised according to clinical practice guidelines. The impact of both strategies on a composite primary endpoint of all-cause mortality, HF hospitalisation and worsening HF will be evaluated during a 36-month follow-up.
This description comes directly from the study's public registry record.
Daniel Rodriguez Muñoz, MD, PhD · +34 917792742 · danielantonio.rodriguez@salud.madrid.org
Ana Isabel Castillo Varón, PhD · +34 917792742 · aicastillo.imas12@h12o.es
Always discuss trial participation with your own doctor first.
| Hospital Universitario 12 de Octubre | Madrid, Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05029570